Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Documenti analoghi

• Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
  di: Udwadia, Zarir F., et al.
  Pubblicazione: (2021)
• Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
  di: Udwadia, Zarir F., et al.
  Pubblicazione: (2021)
• Letter to the Editor
  di: Kotwal, Atul
  Pubblicazione: (2016)
• Correspondence (letter to the editor): Multicenter Study
  di: Thomas, Christine, et al.
  Pubblicazione: (2019)
• Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
  di: Guner, Rahmet, et al.
  Pubblicazione: (2021)